Related Experiment Video
Updated: Aug 19, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis
G C Fonarow1, A Gawlinski, S Moughrabi
1Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, Department of Medicine, Los Angeles, California, USA. gfonarow@mednet.ucla.edu
Insights
The Cardiac Hospital Atherosclerosis Management Program (CHAMP) significantly increased the use of life-saving secondary prevention therapies for coronary artery disease patients after myocardial infarction, improving outcomes.
Area of Science:
- Cardiology
- Preventive Medicine
- Health Services Research
Background:
- Secondary prevention therapies significantly reduce mortality in patients with coronary artery disease.
- These crucial therapies are often underutilized in standard patient care.
- Established coronary artery disease requires effective management strategies to prevent adverse events.
Purpose of the Study:
- To evaluate the impact of the Cardiac Hospital Atherosclerosis Management Program (CHAMP) on the utilization of secondary prevention therapies.
- To assess the effect of CHAMP on clinical outcomes, including low-density lipoprotein (LDL) cholesterol levels, recurrent myocardial infarction, and mortality.
- To determine if CHAMP improves adherence to evidence-based guidelines for post-myocardial infarction care.
Main Methods:
- A Cardiac Hospital Atherosclerosis Management Program (CHAMP) was implemented focusing on guideline-directed medical therapy initiation before hospital discharge.
- Key medications included aspirin, hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins), beta blockers, and angiotensin-converting enzyme (ACE) inhibitors.
- Treatment rates and clinical outcomes were compared between patients before (1992-1993) and after (1994-1995) CHAMP implementation, including LDL cholesterol levels and 1-year mortality.
Main Results:
- Aspirin use increased from 68% to 92%, beta blocker use from 12% to 62%, ACE inhibitor use from 6% to 58%, and statin use from 6% to 86% (all p <0.01).
- The proportion of patients achieving LDL cholesterol <= 100 mg/dl significantly increased from 6% to 58% (p <0.001).
- CHAMP was associated with a reduction in recurrent myocardial infarction and 1-year mortality.
Conclusions:
- The CHAMP program significantly improved the initiation and adherence to secondary prevention medical therapies for patients with coronary artery disease post-myocardial infarction.
- Increased utilization of evidence-based medications and achievement of LDL cholesterol goals led to improved clinical outcomes.
- CHAMP demonstrates an effective strategy for enhancing guideline-directed care and reducing mortality in cardiovascular patients.
Abstract:
Despite scientific evidence that secondary prevention medical therapies reduce mortality in patients with established coronary artery disease, these therapies continue to be underutilized in patients receiving conventional care. To address this issue, a Cardiac Hospital Atherosclerosis Management Program (CHAMP) focused on initiation of aspirin, cholesterol-lowering medication (hydroxymethylglutaryl coenzyme A [HMG CoA] reductase inhibitor titrated to achieve low-density lipoprotein [LDL] cholesterol < or =100 mg/dl), beta blocker, and angiotensin-converting enzyme (ACE) inhibitor therapy in conjunction with diet and exercise counseling before hospital discharge in patients with established coronary artery disease. Treatment rates and clinical outcome were compared in patients discharged after myocardial infarction in the 2-year period before (1992 to 1993) and the 2-year period after (1994 to 1995) CHAMP was implemented. In the pre- and post-CHAMP patient groups, aspirin use at discharge improved from 68% to 92% (p <0.01), beta blocker use improved from 12% to 62% (p <0.01), ACE inhibitor use increased from 6% to 58% (p <0.01), and statin use increased from 6% to 86% (p <0.01). This increased use of treatment persisted during subsequent follow-up. There was also a significant increase in patients achieving a LDL cholesterol < or =100 mg/dl (6% vs 58%, p <0.001) and a reduction in recurrent myocardial infarction and 1-year mortality. Compared with conventional guidelines and care, CHAMP was associated with a significant increase in use of medications that have been previously demonstrated to reduce mortality; more patients achieved an LDL cholesterol < or =100 mg/dl, and there were improved clinical outcomes in patients after hospitalization for acute myocardial infarction.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:26Atherosclerosis III: Management